Paxman crosses SEK 100m as insurance-billing inflection meets an FDA reset
Paxman AB’s Q2 2026 report is the first in its history to land group sales above SEK 100 million, and the tone from CEO Richard Paxman is justifiably buoyant: “group sales amounted to just over SEK 105 million. So we've hit that 100 mark for the first time in our history, which is fantastic.” — Richard Paxman, CEO · 2026-08-21 The 40% year-over-year growth was helped by the Dignitana acquisition (which contributed SEK 5.2 million of EBITDA), but the story is more than a bolt-on. Paxman is finally seeing the insurance-based billing model take hold, turning its scalp-cooling installed base into a recurring-revenue engine with utilization numbers that investors rarely see in this category.
IBBM: Utilization is the real ‘simple switch’
The quarterly metrics highlight is a step-change in U.S. utilization once sites move from self-pay to insurance-based billing. Paxman’s own IBBM sites are treating 8.6 patients per site versus 3.1 for self-pay, and 3.4 per system versus 1.6. That is the Simple Switch thesis made concrete: the same hardware can produce materially more revenue without adding new installations. CEO Richard Paxman explains the shift: “Under IBBM, it sort of changes your mindset. So your oncology team would start to then consider talking about scalp cooling because it's part of that patient pathway. It's more standard of care without an out-of-pocket cost.” — Richard Paxman, CEO · 2026-08-21 The market is responding — IBBM revenue grew 110% year-on-year, and U.S. revenues reached $7.1 million versus $4.0 million in Q2 2025.
The shift is also visible in order books: 190 systems on order, with 80 bound for the U.S. Since U.S. systems are now mostly sold on an IBBM basis, the revenue per system should rise as utilization normalizes. Paxman is also seeing an encouraging cross-sell for Dignitana, which has only begun its own IBBM transition but is already generating better utilization in both models than before.
FDA De Novo: A delay, not a detour
The other big news is a regulatory reroute for the neuropathy device. After originally pursuing a traditional 510(k), the FDA concluded there is no suitable predicate, pushing Paxman into a De Novo submission. Paxman is careful to frame it as a timing step, not a change in opportunity: “They'll ask more questions. I mean that's the process... But building that case, albeit not having a full RCT within our data package yet should result in not needing to do any further clinical trials.” — Richard Paxman, CEO · 2026-08-21 The company intends to submit this month, expects clearance in 8–12 months, and still targets U.S. commercialization in Q2 2027.
The regulatory pathway also strengthens its clinical story. Paxman cites 150-patient Singapore data and continues to recruit a Dana-Farber RCT that could provide interim analysis if the FDA requests more randomized evidence. The company also notes that clinical data from MDR in Europe is a high bar to cross, which should give confidence in the existing evidence package. In parallel, the plan is to deploy version-2 neuropathy units into European pilots in Germany, France, Spain, and the Netherlands by September, keeping the commercial engine warm while the FDA process unfolds.
There is a setback with the De Novo route, but it's just a setback. I think we've got to remind ourselves that the opportunity is still exactly the same as it was a month ago before we knew we were going down the 510(k) route.
Cash and the runway to 2027
Paxman’s balance sheet remains a comfort. The company holds SEK 105 million in cash, and despite incremental investment in neuropathy, commercialization, and new facilities, the cash position is stable. The company’s EBITDA margin, adjusted for CIPN and commercialization costs, was 18.5%, up from the prior year. This financial headroom is what allows Paxman to continue building its reimbursement team, expanding self-pay and IBBM site conversion, and invest in operational excellence ahead of the U.S. launch.
The report also shows healthy rest-of-world demand — the order book includes significant European and Australian contributions — and the first real momentum in the neuropathy clinical program. The De Novo route carries no specific long-term benefit beyond classification, but the CEO emphasizes that the strategic value is unchanged. With several oncology practices already signed to letters of participation and revenue expected in Q4, the company is building tangible traction before the key U.S. commercialization milestone.
For a small-cap medical-device company, the Q2 report is a meaningful inflection: a first triple-digit-revenue quarter, accelerating insurance-based billing, and a regulatory delay that is being managed with patience and a clear plan. Paxman is not out of the woods — FDA schedules are unpredictable — but it is moving from promise to execution. The mix of a 110% IBBM revenue jump and a 40% total revenue increase should give investors a reason to keep watching.